Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATEWAYII: Rituximab Induction Followed by Glatiramer Acetate in MS
NCT01569451Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Feb 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in multiple sclerosis (MS), clinically isolated syndrome (CIS), sponsored by University of Colorado Denver. Started Feb 2012; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT01569451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01569451.